Johnson & Johnson (NYSE:JNJ) Shares Down 1.3% - Here's Why

Key Points

• Q1 results: J&J reported $2.70 EPS (vs. $2.68 est.) and $24.06B revenue (vs. $23.60B est.), with revenue up 9.9% year-over-year and FY‑2026 guidance set at 11.450–11.650 EPS (analysts expect ~11.57).
• Dividend boost: The quarterly dividend was raised to $1.34 ($5.36 annualized) for a ~2.4% yield, with an ex-dividend date of May 26 and a payout ratio near 62%.
• Analyst sentiment: Street coverage is largely positive (18 Buys, 9 Holds), an average price target of $252.48, and several banks have recently raised targets (Goldman to $275).

Johnson & Johnson (NYSE:JNJ - Get Free Report) was down 1.3% on Monday . The company traded as low as $223.58 and last traded at $224.1470. Approximately 7,978,478 shares traded hands during mid-day trading, a decline of 7% from the average daily volume of 8,548,951 shares. The stock had previously closed at $227.19.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on JNJ shares. TD Cowen started coverage on Johnson & Johnson in a report on Wednesday, April 8th. They issued a "buy" rating and a $250.00 price target for the company. Daiwa Securities Group boosted their price target on Johnson & Johnson from $237.00 to $246.00 and gave the company an "outperform" rating in a report on Thursday, April 16th. The Goldman Sachs Group boosted their price objective on shares of Johnson & Johnson from $265.00 to $275.00 and gave the company a "buy" rating in a research report on Wednesday, April 15th. Scotiabank reaffirmed an "outperform" rating on shares of Johnson & Johnson in a research report on Thursday, January 22nd. Finally, Loop Capital set a $220.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, January 27th. Eighteen analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $252.48.

Johnson & Johnson Stock Performance

The stock has a market capitalization of $539.57 billion, a P/E ratio of 25.91, a P/E/G ratio of 2.23 and a beta of 0.27. The stock has a 50 day moving average of $238.83 and a 200 day moving average of $219.90. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The firm had revenue of $24.06 billion during the quarter, compared to analysts' expectations of $23.60 billion. During the same quarter in the prior year, the firm earned $2.77 EPS. Johnson & Johnson's quarterly revenue was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Equities analysts predict that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be given a $1.34 dividend. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.30. The ex-dividend date is Tuesday, May 26th. This represents a $5.36 annualized dividend and a yield of 2.4%. Johnson & Johnson's payout ratio is currently 61.97%.

Insider Activity

In other news, EVP Timothy Schmid sold 22,623 shares of the stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total value of $5,527,477.59. Following the completion of the transaction, the executive vice president owned 26,769 shares of the company's stock, valued at approximately $6,540,469.77. This represents a 45.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the transaction, the executive vice president directly owned 23,003 shares of the company's stock, valued at approximately $5,598,700.17. The trade was a 21.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 30,142 shares of company stock valued at $7,360,528. 0.16% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of JNJ. Auto Owners Insurance Co boosted its holdings in shares of Johnson & Johnson by 22,225.6% in the fourth quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company's stock valued at $1,436,633,000 after acquiring an additional 69,108,368 shares in the last quarter. Norges Bank bought a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $6,924,523,000. Capital World Investors bought a new position in Johnson & Johnson during the fourth quarter valued at about $2,005,942,000. Diamant Asset Management Inc. boosted its stake in Johnson & Johnson by 24,436.5% during the first quarter. Diamant Asset Management Inc. now owns 4,473,008 shares of the company's stock valued at $109,338,000 after buying an additional 4,454,778 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in Johnson & Johnson by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company's stock valued at $49,740,362,000 after buying an additional 3,731,074 shares in the last quarter. Institutional investors own 69.55% of the company's stock.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.